Quick Answer
Avalo Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $15.86 million for the year ending 2025.
- Avalo Therapeutics, Inc. showed a decrease of -88.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Avalo Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Avalo Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 66.6%.
- Historical annual values: Fiscal year 2025: $15.86 million | Fiscal year 2024: $134.55 million | Fiscal year 2023: $7.42 million | Fiscal year 2022: $13.17 million | Fiscal year 2021: $54.59 million | Fiscal year 2020: $18.92 million | Fiscal year 2019: $3.61 million | Fiscal year 2018: $10.65 million | Fiscal year 2017: $2.47 million | Fiscal year 2016: $5.13 million | Fiscal year 2015: $21.16 million | Fiscal year 2014: $11.74 million | Fiscal year 2013: $3.42 million | Fiscal year 2012: $9.52 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: